Efficacy and Safety of Oral Semaglutide Therapy in Adults With Overweight or Obesity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet 2023 Jun 23;[EPub Ahead of Print], FK Knop, VR Aroda, RD do Vale, T Holst-Hansen, PN Laursen, J Rosenstock, DM Rubino, WT GarveyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.